Member Info for Yorkshireboy

NEXO: Hyundai’s hydrogen fuel-cell first | Hyundai News | Hyundai Australia

The Hyundai NEXO Fuel Cell Electric Vehicle (FCEV) has arrived - the first hydrogen-powered vehicle certified for sale in Australia

https://www.hyundai.com/au/en/news/vehicles/nexo-hyundai-hydrogen-fuel-cell-first

Experts emphasize that Toyota's management has long indicated the necessity of striving for emission reductions most efficiently, rather than becoming unwavering advocates of electrification at all costs. To this end, the Japanese company, in collaboration with the Chinese conglomerate Guangzhou Automobile Group (GAC Group), has already invested £4.8 billion in efforts to implement ammonia combustion engine technology for mass production.

https://www.msn.com/en-gb/cars/news/toyota-and-gac-unveil-ammonia-engine-the-end-of-electric-cars/ar-BB1ohMJQ?ocid=socialshare&pc=U531&cvid=7a5905e47bbb4175a1f8b73b2ceca1f8&ei=36

Https://www.thearmchairtrader.com/uk-shares/powerhouse-motors-through-gears-bridgend/

GLA

Https://www.proactiveinvestors.co.uk/companies/news/1048931/powerhouse-energy-to-see-sales-boost-from-australian-partnership-1048931.html?rel=scroll

GLA

today, tissue regenix ceo daniel lee introduced a talk about hashtag#orthopure xt at the geistlich pharma lunchtime symposium at the esska - european society of sports traumatology, knee surgery & arthroscopy congress in milan, italy.

prof. stefano zaf***nini also shared his experiences and short-term results with orthopure xt for hashtag#acl reconstruction.

for more information, please visit the website: https://lnkd.in/ekzzanby

hashtag#esska2024

hashtag#esskacongress

March 2024

Environmental Management Plan for the Proposed Hope & Gorob Mining Project for ML 246 on EPL 5796 in the Namib Naukluft National Park, Erongo Region

This document details the Environmental Management Plan (EMP) or the management actions needed to avoid or lessen identified impacts to acceptable standards as informed by the Environmental and Social Impact Assessment (ESIA).

Ctrl +Click to follow link.

ENVIRONMENTAL MANAGEMENT PLAN (the-eis.com)

Major new fuel source ‘shows great potential’ as alternative to petrol and diesel (msn.com)

A new fuel source could be used in vehicles in the future with experts calling for more research and development to be done.

Ammonia is a zero-carbon fuel and has been touted by some as being a suitable and sustainable alternative fuel for the future of transport.

A new fuel source could be used in vehicles in the future with experts calling for more research and development to be done.

Ammonia is a zero-carbon fuel and has been touted by some as being a suitable and sustainable alternative fuel for the future of transport.

Major new fuel source ‘shows great potential’ as alternative to petrol and diesel (msn.com)

Rishi Sunak backs hydrogen vehicles after warning that UK was being 'left behind' by EU and US (msn.com)

Https://www.gbnews.com/lifestyle/new-hydrogen-vehicle-toyota-hilux-uk

Although relatively small, this was actually a Buy (and not a Sell). I wish I could have afforded to purchase more, thereby, reducing my average further. Hopefully, I can take advantage of this ridiculously low price again in the near future.

GLA.

Https://www.businessweekly.co.uk/news/biomedtech/sareum-oozing-confidence-upcoming-trials

Olivier Mussat: - We are playing in a $200b market.

https://www.voxmarkets.co.uk/media/64c25c40f10a196061864964/?context=/series/daily-podcast

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren’t Fully Effective – OKYO Pharma’s Drug Candidate Could Be The Solution - OKYO Pharma (NASDAQ:OKYO) - Benzinga

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution | Benzinga
Good Luck Everyone

Soup I have previously admired some of your previous posts but unfortunately you have gone down in my estimation and do not take any pleasure in saying that. I have no problem with anyone criticising my posts if it can be justified, as no one is infallible. However, I feel you are spending to much time trying to impress on this BB and I hate to say it but you may have lost the plot or are trying to play games or you just need to go to spec savers. You appear to be taking things I have posted too personally, which has never been my intention.

I take no satisfaction in highlighting discrepancies made by a fellow poster, but I would suggest you proofread what you write, as your post Today 17:31 is pure nonsense. ‘Unfortunately I fear you may have not understood that Canadian government documents use the format YYYY-MM-DD, whereas your post (6 jul 22:33) works on the YYYY-DD-MM, therefore your timings are essentially wrong.’

Ref: see national Standards Council of Canada for confirmation.
https://www.scc.ca/en/standardsdb/standards/4449

This would mean that the first patent #1 (CA 2846460) was issued prior to any deal with Ebers. So is not relevant as you thought as it is dated January, not September.

I often refer to myself as a ‘Simple Yorkshire Lad’ but that cannot be further from the truth, so please don’t try to take the p**s. I have forgotten more about pharmaceutical research than you will ever know and would advise you to read my post again. Yes if I ever quote dates etc I always transpose these into my native timeline and that of the audience who will be reading it. The following is my exact transcript (you quote), which is completely different from what you are trying to insinuate: -

‘This #1 Patent for Ebers was granted patent status and issued on 01/08/2019 although we were not notified of it until 9th September 2019 RNS Number 6247L.’

Please feel free to check all my posts as then I will not have to worry about grammatical/spelling irregularities. I have not taken my bat and ball home and will continue to post information relevant to my investments as I think fit. Although, I will not be concerned whether you read them or not, however, if you post anything relevant, I will applaud you for sharing it. Good luck, stay well and let us please support NFX in achieving their objectives, not in ‘tit for tat’ correspondence. YB

Soup my apologies for not being able to reply earlier, but sometimes business dictates how much time we can give to other life areas. I hope you are well and enjoying the NFX ride, it reminds me a bit of the ‘Big Dipper’ at Blackpool pleasure beach with its ups/downs and the occasional settled moments. Personally, I’m enjoying the experience although I appreciate that for some it can be fraught at times. I will try and ensure that this post doesn’t turn into one of the ‘Bronte’ (by the way riosurfer an excellent post} novels, but unfortunately, I can’t promise.

Unfortunately, I find myself a little discombobulated by your post on 06 July 2020 23:01 as I did not realise that we ‘are in disagreement’! However, it would be of great help to myself and I’m sure others if you can please clarify/expand on your statement ‘Two points, look up what ‘Aprepitant’ is and you’ll find it’s relating to NXP001 and nothing to do with Ebers.’

Therefore, I would like to ask a genuine question. I agree it is very much associated with NXP001, especially within the growing oncology supportive care market. Does that mean it is restricted to this specialist market? If so, I sincerely apologise as it means I have completely misunderstood, because under the English Abstract and Claims section it states: -
’The 1:1:1 aprepitant L-proline H20 composition or cocrystal may be used in the same way as aprepitant to treat or prevent disorders relating to emesis, a neuropsychiatric disease, an inflammatory disease, pairs, cancer, a skin disease, itch, a respiratory disease, or an addiction.’

You may also be correct that it is ‘nothing to do with Ebers’? However, my assumption/hypothesis has been that news released by NFX means that certain patent milestones have been achieved and the timeline fits this, with the patent ownership remaining with the current owners Nuformix. I am sure we both try to post informative and evidence-based facts which may be beneficial for investors. Therefore, I have no problem if you disprove my hypothesis if investors receive the appropriate information.

Good luck and keep well.
YB

Now some of outstanding issues (especially funding) have been resolved, TRX are in an enviable position to provide safe and effective interventions with their broad portfolio of regenerative medicine products. Especially in this speciality which has devastated the quality of life of so many women. In addition to the altruistic reasons, I am sure that TRX will ensure significant financial return to true long-term holders. Also, I wish all the best to those whom bought in the successful fundraising of £14.6 million and are now selling and taking their small profits. Although it surprises me when there is such future potential and fortunately managed a top up yesterday and patiently wait for significant returns, hopefully starting by the end of this year!

Good luck keep well and please DYOR.
YB

Following the publication of the review launched in 2018, entitled "First Do No Harm" is long overdue and I hope the people (mainly woman) who have suffered (potentially of malpractice) at least receive some redress that they deserve. Although I would imagine that nothing would compensate for the years of crippling, life-changing complications including chronic pain, infections, and loss of sex life. Listening to some of the interviews today, some expressed the desire that hopefully others would not have to endure what they had gone through.

I and others posted about this very issue on the 21st January 2020 ‘The future potential of dcell Technology is vast’:- (There are several links (although may now be slightly dated) incorporated into the post which may be useful as an ‘aide de memoire’ for long term holders and advantageous to new investors. Who could be selling their share at what some may feel is an undervalued price? I have included the first couple of initial paragraphs of the post below, although the full text etc, can be found on my posting history)

‘As shown by the excellent video posted by Boom123 today, there are significant issues associated with Urogynaecology mesh which is used to treat stress incontinence and pelvic organ prolapse. The very same product used in vaginal mesh surgery currently facing a number of lawsuits worldwide has been, and is currently being used, in hernia operations.
https://www.nhsnegligence.co.uk/hip-knee-spine-implants/hernia-mesh-implants/

As highlighted by the video a safe, effective, and endorsed alternative is urgently required and that is already available as most investors in TRX and the medical profession are becoming more and more aware. I.e.: - dCELL® technology A Decellularised Dermal Allograft is used to Manage a Patient's Soft Tissue Defects. Intended to be used to provide reinforcement, repair, or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument. female pelvic medicine & reconstructive surgery.’

Then following some excellent contributions by fellow posters on 21st February 2020 I posted, ‘RE: Publicity and opportunities for TRX?’

Large Number of women with transvaginal mesh require surgeries years later. (February 19th, 2020)
'An alarmingly high percentage of women who received transvaginal mesh implants to treat pelvic organ prolapse (POP) require additional surgeries years after being implanted with the devices, suggesting that problems with the devices won’t end anytime soon despite the removal of mesh for POP from the market last year.’
https://www.beasleyallen.com/news/large-number-of-women-with-transvaginal-mesh-require-surgeries-years-later/
’Empowering Surgeons’ which includes some excellent testimonials.’
https://www.armsmedical.com/surgeons/

To be continued

The third of the three is #3 = Patent CA 2908440 = TRANILAST COMPOSITIONS AND COCRYSTALS. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
Soup I believe this is the one you queried in your post of 17:02. I must admit that initially I had questions as to why after being filed with WIPO on 29/03/2013 it was given a Canadian filing date – 30/09/2015 to which I could not find the answer. On my previous posts ‘Developments are Developing’ 11 May 2020 I made no reference to Ebers, just that it was one of three patent documents submitted to the Canadian Intellectual Property Office (CIPO). Although I added a comment that ‘Interestingly this is for ‘Tranilast Compositions’ but had no indication that it was related to Ebers. Due to lack of evidence I did not want to be accused or associated with another fiasco like October 2019. It was not until I read Greggs post that I thought there could possibly be some link (especially due to the time framework), although this is pure speculation on my part. Just to clarify Soup, the official request for examination/amendments of #3 was from October 2019 and the amendments were submitted on the 9th April 2020. As far as I am aware NFX are still waiting for the official response and when it arrives I’m sure it will be positive and NFX will inform us at the appropriate time.
Soup I know you are a genuine poster and sounds like you may be from Yorkshire. Normally I would not have responded to this depth and degree but if it positively informs genuine investors then its worth it. However, please note I’m only a simple Yorkshire Boy albeit from Gods own country and I’ve used up my full vocabulary today, so please don’t make a habit of it. Wow, I deserve that glass of fine Malt, goodnight, good luck all, and sorry if I’ve bored anyone. YB

Hi Soup, many thanks for your comments and hopefully the following will clarify any issues. The following link identifies that so far there has been 3 specific Patent submissions to the Canadian Intellectual Property Office (CIPO). We must also keep in mind that they may have been filed at an earlier date with other organisations i.e. World Intellectual Property Office (WIPO) etc who may have been one of the first points of contact re Intellectual Property. Hopefully, this should address your query posted at 16:42?

Soup you will probably be aware of the following, so I do apologise. However, I’m sure there will be others who may benefit by the structured information. As unfortunately it can be a little confusing as I initially found out: -
https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=Nuformix

On this page you will note that in the left-hand First column each one is identified by the # Number in descending order (1, 2 & 3) followed by Second column # Patent (which is the Patent identification number) in descending order relating to the # number, and the Third is the Patent Title in descending order, obviously relating to both # number and # Patent

Therefore, the First #1 = # Patent CA 2846460 = APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL’.
Click on the # Patent number and it takes you to the Patent information page. This provides a basic summary of the submission data, usually starting with the Bibliographic Data, if you ‘hover’ over the left-hand column headings, it gives you a brief description as to what it relates too. If you want additional information, (especially the science etc) click on the required boxes (white on a black background) Bibliographic Data, Abstracts, Claims etc, etc which are in row across the page.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html?query=Nuformix&type=
This #1 Patent for Ebers was granted patent status and issued on 01/08/2019 although we were not notified of it until 9th September 2019 RNS Number 6247L.
The second is #2 = Patent CA 2892832 = APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS’. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2892832/summary.html?query=Nuformix&type=
This #2 is the second Patent for Ebers and was initially filed with WIPO on 21/11/2012 and then granted patent status and issued by the CIPO on 14/04/2020 although we were not notified of it until 27th May 2020 RNS Number: 0476O.

The third of the three is #3 = Patent CA 2908440 = TRANILAST COMPOSITIONS AND COCRYSTALS. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
Continued